HEOR: From Proving Product Value to Proving Its Own Worth
Published: | Updated:
The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.
Sarah Bandy, PhD
Advertisement
Sarah Bandy, PharmD, PhD is a Manager, Value Evidence, AESARA Inc.
Articles by Sarah Bandy, PhD
Advertisement
Latest Updated Articles
HEOR: From Proving Product Value to Proving Its Own WorthPublished: March 6th 2025 | Updated: May 7th 2025
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: FDA Approves Hernexeos
2
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
3
FDA Approves Hernexeos Under National Priority Voucher Program
4
FDA Approves Dupixent as First Treatment for Allergic Fungal Rhinosinusitis in Adults and Children
5